Award & Investment Overview
The University of Michigan Department of Biomedical Engineering has awarded $950,000 in FY27 funding to nine multidisciplinary teams through its Coulter Translational Research Partnership Program, supporting biomedical technologies moving from university laboratories toward commercial development and clinical practice.
Established with a $20 million endowment in 2005, the U-M BME Coulter program combines translational funding with commercialization guidance, milestone development, and external advisory support. The FY27 portfolio includes technologies spanning hemorrhage control, regenerative medicine, neuromodulation, cardiovascular devices, cancer treatment, ophthalmic diagnostics, spinal cord injury, and AI-enabled diagnostics.
The program also reports substantial downstream commercialization outcomes from previously funded technologies, including six FDA approvals, 20 exits, and more than $2 billion raised in angel and venture capital by startups developing Coulter-supported technologies or generated through company sales.
The combination of current translational funding and documented downstream outcomes makes the program a useful example of a mature university GAP funding model built around both capital and active commercialization support.
Approach & Ecosystem Context
The Coulter Translational Research Partnership Program supports technologies progressing from laboratory research toward commercial development and clinical use.
Its model extends beyond individual project awards. Teams receive support beginning at the proposal stage and continue working with program leadership during funded development. An external Coulter Advisory Board contributes to project evaluation, commercialization guidance, and milestone development.
The program also intentionally brings engineering and clinical investigators together. Each of the nine FY27 projects pairs biomedical, mechanical, chemical, electrical, or computer engineering expertise with clinical expertise in areas including emergency medicine, internal medicine, neurosurgery, cardiovascular medicine, urology, ophthalmology, and radiology.
From a GAP perspective, this multidisciplinary structure addresses an important translational challenge. Biomedical technologies require more than technical validation. Clinical workflow, unmet need, regulatory strategy, product design, reimbursement, market adoption, and follow-on financing can all influence whether laboratory research becomes a viable medical product.
The program’s reported history of FDA approvals, startup financing, and exits provides evidence that its role extends beyond research funding into longer-term commercialization outcomes.
Innovation & Technology
The FY27 portfolio includes nine distinct translational projects.
Nicholas Kotov and J. Scott VanEpps are developing “Armaclot: A Rapid Hemostatic Agent for Uncontrollable Hemorrhage,” focused on rapid control of severe bleeding.
Brendon Baker and Scott Soleimanpour are advancing the “Vascular Integration System for Therapeutic Application (VISTA),” a platform centered on vascular integration for therapeutic applications.
Scott Lempka and Kevin Chen are developing “An Optimization Framework for Precision Spinal Cord Stimulation,” applying a more precise approach to spinal cord stimulation.
Albert Shih and Eric Cantey are advancing “A Low-Profile, Expandable, and Durable Percutaneous Ventricular Assist Device (MiVAD),” targeting cardiovascular support through a percutaneous device platform.
Guan (Gary) Xu and Andrew Wood are developing “Guided Prostate Cancer Focal Therapy with a Photoacoustic Imaging Needle,” combining focal prostate cancer treatment with photoacoustic imaging guidance.
Volker Sick and Angela Verkade are advancing “Diagnosing Keratoconus and Ectasia by Inverting Corneal Shadowgrams,” targeting improved diagnosis of corneal disorders.
Kenn Oldham and Florian Schmitzberger are developing the “Systolic Target Assessment Tool (STAT).” The supplied announcement does not provide additional detail on the technology or intended clinical use.
Lonnie D. Shea and Noojan Kazemi are developing an approach using polyethylene glycol microporous annealed particle tubes to stimulate neuroregeneration through spinal cord injury sites.
Liyue Shen and Steven Soliman are developing an “AI-Driven Muscle Ultrasound and Multimodal Data Fusion Device for Early Detection and Personalized Risk Stratification of Metabolic Dysfunction,” combining ultrasound, multimodal data, and AI for earlier detection and individualized assessment.
Potential Market Uses and Applications
Potential Emergency and Acute Care Applications
- Rapid hemorrhage control
- Emergency medicine
- Severe bleeding management
Potential Therapeutic and Regenerative Medicine Applications
- Vascular integration
- Therapeutic delivery or support
- Spinal cord neuroregeneration
- Spinal cord injury treatment
Potential Neuromodulation Applications
- Precision spinal cord stimulation
- Neuromodulation optimization
- Personalized stimulation planning
Potential Cardiovascular Applications
- Percutaneous ventricular assistance
- Mechanical circulatory support
- Cardiovascular intervention
Potential Oncology Applications
- Prostate cancer focal therapy
- Photoacoustic image guidance
- Precision cancer intervention
Potential Ophthalmology Applications
- Keratoconus diagnosis
- Corneal ectasia diagnosis
- Corneal imaging and assessment
Potential Diagnostic Applications
- Muscle ultrasound
- Metabolic dysfunction detection
- Personalized risk stratification
- AI-enabled multimodal diagnostics
The supplied announcement does not provide enough information to assign specific Potential market applications to STAT beyond its stated project title.
Related Topics
University of Michigan, Michigan Biomedical Engineering, Coulter Translational Research Partnership Program, Coulter Program, translational research, GAP funding, proof of concept, biomedical engineering, medical devices, therapeutics, university commercialization, technology transfer, clinical translation, translational funding
About innovosource
innovosource tracks GAP programs, including proof-of-concept programs, startup accelerators, translational research initiatives, university venture funds, and commercialization ecosystems that help move university innovations from research to market.
Our coverage is informed by the Mind the GAP initiative and GAP COA consortium activity, providing practical insights into the evolving commercialization landscape.
Learn more:
